LP-10

Lipella Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	LP-10
Sponsor	Lipella Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Methylphenidate and Cognitive Training in Elderly (PHASE2)
Evaluating LP-10 in Subjects With OLP (PHASE2)
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis (PHASE2)
The Interaction Between Protein Intake, Gut Microbiota and Type 2 Diabetes in Subjects With Different Ethnic Backgrounds (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LP-10 CI brief — competitive landscape report
LP-10 updates RSS · CI watch RSS
Lipella Pharmaceuticals, Inc. portfolio CI